Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZMO -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (190)	12/10/1999 9:53:00 AM
From: biowa	Read Replies (1) \| Respond to of 438

Mike, You obviously weren't in the Army (neither was I). Never volunteer; but since you did: 1) Does GZMO have exlusive ownership of SAGE? What residual rights does GENZ have? What IP rights/royalties on discoveries does GZMO typically get from SAGE licensees? 2) In the recent Nature Genetics PR, GZMO says that 46% of the transcripts found are from genes not in existing databases. Could they clarify what they mean be "existing databases?" If these are truly undiscovered genes does GZMO (or JHU) plan to pursue any patent protection on them? Is there any patent protection on transcripts identified? Thanks, biowa

To: Mike McFarland who wrote (190)	12/10/1999 10:02:00 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 438

Mike: We mostly hear about the biologicals programs, ATIII and the vaccines. I consider these to be leverage, and want to know most about any efforts to move small molecule stuff toward preclinical studies. The II Forums are lousy places to ask questions in the general forum. You can, however, dog a presenter after he or she is finished, particularly if you're willing to miss a part of the next presentation. So..... I'd be interested in MORE than the usual BS outline of small molecule work, in specifics about lead development, etc. If you get a chance, thanks! Rick